Low-Dose Aspirin Adjunct in Bipolar Depression: Promising Phase II Signal, Fragile Long-Term Data
This phase II trial gives pharmacists the first randomised signal that acetylsalicylic acid (ASA) 150 mg/day may add antidepressant and relapse-prevention benefit in bipolar depression, with important caveats on attrition and generalisability.
📅 Journal publication: Oct 27, 2026·Last updated: Nov 16, 2026
Could low-dose aspirin be a game-changer for bipolar depression?
Bipolar depression is challenging to manage, with few effective therapies available for acute and preventative treatment. ASA 150 mg/day improved depressive symptoms at 2 months (p = 0.005) and reduced relapse at 12 months (p = 0.026). While promising, this phase II study requires further validation in larger phase III trials before changing practice. Low-dose aspirin might aid in bipolar depression symptom relief and relapse prevention.
📊 Deep Analysis Available
Subscribers get the full breakdown: study design, outcomes, pharmacist implications, clinical pearls, GRADE evidence grade, and a downloadable PDF report. Cancel anytime.
Free account, no credit card. Includes 1 full deep analysis every month.
Authors:Dominiak M, Antosik AZ, Gędek A, Krawczyk-Syguda A, Biedrzycki S, Kuczyńska J, Dermanowski M, Mierzejewski P
Citation:Dominiak M, Antosik AZ, Gędek A, et al. Adjunctive Low-Dose Acetylsalicylic Acid in Bipolar Disorder: A Multicentre, Randomised, Double-Blind, Placebo-Controlled Phase II Trial (ASPIRIN BD). Journal of clinical medicine. 2026;15(21). doi:10.3390/jcm15218349